![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics.
TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...
TEL AVIV, Israel, June 26, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...
Reaches 50% enrollment in the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in Q3 2024 TEL AVIV, Israel, May 15, 2024 (GLOBE...
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...
TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd.Β (Nasdaq: PRFX) (βPainReformβ or the βCompanyβ), a clinical-stage specialty pharmaceutical company focused on the...
TEL AVIV, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd.Β (Nasdaq: PRFX) (βPainReformβ or the βCompanyβ), a clinical-stage specialty pharmaceutical company focused on the...
TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1036 | -19.6958174905 | 0.526 | 0.56 | 0.379 | 356773 | 0.42621442 | CS |
4 | -0.0776 | -15.52 | 0.5 | 0.599 | 0.379 | 174408 | 0.45635536 | CS |
12 | -0.5076 | -54.5806451613 | 0.93 | 0.966 | 0.379 | 179758 | 0.59099552 | CS |
26 | -1.5476 | -78.5583756345 | 1.97 | 2.55 | 0.379 | 152952 | 0.99351256 | CS |
52 | -7.0076 | -94.3149394347 | 7.43 | 8.59 | 0.379 | 98664 | 1.91714879 | CS |
156 | -35.3776 | -98.8201117318 | 35.8 | 41 | 0.379 | 276931 | 14.07427417 | CS |
260 | -66.2776 | -99.3667166417 | 66.7 | 78.4 | 0.379 | 320591 | 23.19773991 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions